During the past decade, The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" #1 sponsor was "C. R. Bard" with 1 trials, followed by "CHDI Foundation, Inc." with 1 trials sponsored, "Eisai Inc." with 1 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 1 trials sponsored and "Rutgers, The State University of New Jersey" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "University of Alabama at Birmingham" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" are "Arteriovenous Fistula" (1 trials), "Atherosclerosis" (1 trials), "Carotid Stenosis" (1 trials), "Cerebral Infarction" (1 trials) and "Depressive Disorder, Major" (1 trials). Many other conditions were trialed in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" in a lesser frequency.

Most popular intervention types in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" are "Device" (2 trials), "Drug" (2 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carotid Artery Stenting (CAS)" (1 trials), "Carotid Endarterectomy (CEA)" (1 trials), "Lutonix DCB" (1 trials), "Perampanel" (1 trials) and "Percutaneous Transluminal Angiography" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham" are 5 trials for "All" genders.

Currently, there are NaN active trials in "The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".